Also, p53 gene mutations and a dysregulated p53 pathway in the context of CRC have been associated with more invasive and metastatic disease, poorer prognosis, resistance to chemotherapy, etc. [51]. The gene discussed is TP53; the disease is metastatic neoplasm.